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Virus evolutionsition towards virus extinction mediated by enhanced mutation rates during viral
genome replication. Theoretical studies suggest that viruses can evolve towards regions of their ﬁtness
landscapes at which they display resistance to the deleterious effects of mutations. It has been suggested that
such mutational robustness could jeopardize lethal mutagenesis. We have used the Arenavirus lymphocytic
choriomeningitis virus (LCMV) to explore whether treatment with the mutagenic base analogue 5-
ﬂuorouracil (FU) selected for viral populations displaying resistance to lethal mutagenesis. Neither average
LCMV populations with a history of FU mutagenesis, nor individual biological LCMV clones derived from
those populations, displayed any resistance to lethal mutagenesis by FU. They were as sensitive to FU-
induced extinction as LCMV populations and clones treated in parallel, but without a history of FU
mutagenesis. Current evidence of the molecular events affecting quasispecies dynamics suggests that it is
unlikely that a viral population can acquire mutational robustness under the increased mutation rates
associated with mutagenic treatments. We consider mechanisms by which viruses could escape extinction by
lethal mutagenesis, and provide evidence that mutational robustness is unlikely to be one of them.
© 2008 Elsevier Inc. All rights reserved.Introduction
RNAviruses replicate as dynamic distributions of closely relatedbut
non-identical genomes, termed viral quasispecies, in agreement with
predictions of quasispecies theory, developed initially to explain self-
organization and adaptability of early replicons as primitive life forms
(Eigen, 1971; Eigen and Schuster, 1979; Eigen et al., 1988; Figlerowicz
et al., 2003; Holland, 2006; Nowak, 2006; Biebricher and Domingo,
2007). The understanding of RNAviral populations as quasispecies has
been instrumental to interpret virus adaptability and mechanisms of
viral pathogenesis [reviews in Domingo et al., 2001, 2008; Holland,
2006]. One of the predictions of quasispecies theory is that there is a
link between ﬁdelity of viral replication and genome complexity,
through an error threshold for maintenance of genetic information
(Eigen and Schuster, 1979; Eigen et al., 1988; Biebricher and Eigen,
2005; Nowak, 2006). The error threshold deﬁnes a maximum average
error rate compatible with maintenance of the instructions conveyed
by an organized quasispecies. Persistent violation of the error thresh-




l rights reserved.reconstruct new quasispecies, results in complete loss of information
(Eigen and Biebricher, 1988; Eigen, 2002; Biebricher and Eigen, 2005).
In the case of viruses, crossing such an error threshold by increasing
the mutation rate during virus replication, should result in virus
extinction. This prediction has been validated experimentally with
several virus–host systems in cell culture and in vivo, and has led to the
development of a new antiviral strategy termed lethal mutagenesis
[Holland et al., 1990; Loeb et al., 1999; Harris et al., 2005; reviews in
Graci and Cameron, 2002; Anderson et al., 2004; Domingo, 2005].
Alternative models that do not relate lethal mutagenesis to the
quasispecies error catastrophe, and that emphasize a demographic
component that unavoidably accompanies viral extinction, have also
been proposed [reviewed in Bull et al., 2008].
Previous studies on the events underlying the extinction of
lymphocytic choriomeningitis virus (LCMV) and foot-and-mouth
disease virus (FMDV) by mutagenic nucleotide analogues have led to
the following observations [summarized from Domingo et al., 2008]:
(i) Extinction occurs with decreases of 102- to 103-fold in speciﬁc
infectivity, and without modiﬁcation of the consensus nucleotide
sequence of the viral population (González-López et al., 2005; Grande-
Pérez et al., 2005a). (ii) Low viral load and low viral ﬁtness favor
extinction (Sierra et al., 2000; Pariente et al., 2001). (iii) Mutagenic
activity, and not only the inhibitory activity that is often associated
with it, is necessary to achieve extinction (Pariente et al., 2003;
Escarmís et al., 2008). (iv) Interfering interactions among components
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López et al., 2004; Grande-Pérez et al., 2005a,b; Perales et al., 2007).
Participation of a class of interfering genomes, termed defectors, in
viral extinction was supported by the observation that loss of
infectious LCMV preceded loss of replicating LCMV RNA, and by in
silico simulations of the fate of infectious genomes in the course of viral
replication in the presence or absence of interfering genomes (Grande-
Pérez et al., 2005b).These results led to the proposal of the lethal defec-
tionmodel of virus extinction. Interferencewithin quasispecies has been
observed also with pre-extinction FMDV populations (González-López
et al., 2004), with speciﬁc capsid and polymerase mutants of FMDV
(Perales et al., 2007), and with several proteins and the cre replication
RNA element of poliovirus (PV) (Crowder and Kirkegaard, 2005). At low
mutagenic intensities, virusmaygo extinct by the action of defectors, and
at high mutagenic intensities, the system may collapse as a result of
increasing interfering interactions, and also of lethal mutations that
eliminate viable genomes (González-López et al., 2004; Arias et al., 2005;
Grande-Pérez et al., 2005a,b; Takeuchi and Hogeweg, 2007).
A critical issue regarding lethal mutagenesis as an antiviral strategy
is whether virus mutants resistant to the mutagenic activities can be
selected, and whether they can jeopardize extinction. Mutant RNA
viruses with decreased sensitivity to inhibitors of viral replication are
almost universally selected in cell culture and in vivo, due to the
combined effects of high mutation rates during viral replication and
the requirement of one or very few mutations to decrease virus
sensitivity to an antiviral inhibitor (Domingo, 2003; Figlerowicz et al.,
2003). PV, hepatitis C virus (HCV) and FMDV that show resistance
to the nucleoside analogue ribavirin (1-β-D-ribofuranosyl-1, 2, 3-
triazole-3-carboxamide) –which is mutagenic for these viruses–, have
been selected and the relevant mutations were located in the
corresponding viral polymerases (Crotty et al., 2000, 2001; Pfeiffer
and Kirkegaard, 2003; Vo et al., 2003; Young et al., 2003; Freistadt
et al., 2004; Castro et al., 2005; Pfeiffer and Kirkegaard, 2005b,a;
Vignuzzi et al., 2006; Sierra et al., 2007). The administration of FU to
mice can prevent the establishment of a persistent infection in vivo.
This experiment represented the ﬁrst evidence of the feasibility of a
lethal mutagenesis approach in vivo (Ruiz-Jarabo et al., 2003).
Ribavirin acted as a potent inhibitor of LCMV replication, and no
mutagenic activity could be documented (Ruiz-Jarabo et al., 2003).
The effects on the levels of viral replication and particle production of
treatments with ribavirin and FU suggest different mechanisms of
action (Ruiz-Jarabo et al., 2003). Although mutations that decrease
sensitivity to mutagenic nucleotide analogues are likely to diminish
the effectiveness of lethal mutagenesis treatments, the effect of
mutations that confer resistance to ribavirin on virus extinction has
not been quantiﬁed. It should be also considered that resistance
mutations often entail a ﬁtness cost and that low ﬁtness virus in vivo
could be easier to clear by the host immune responses.
An alternative mechanism that has been proposed to act against
extinction by lethal mutagenesis is robustness (Sanjuan et al., 2007).
Robustness has been variously deﬁned as the invariance of phenotypes
in the face of perturbation (de Visser et al., 2003) or, more speciﬁcally
for the case of viruses, as phenotypic constancy in the face ofmutational
changes in the genome (Montville et al., 2005). Two populations of
vesicular stomatitis virus (VSV) manifested different sensitivity to 5-
ﬂuorouracil (FU)mutagenesis, attributed to oneof thepopulations lying
on a ﬂat ﬁtness surface that rendered the virus less sensitive to the
deleterious effects of mutations (Sanjuan et al., 2007). Fitness surface
refers in this case to the shape that values of replicative capacity will
follow when genetic variations of the virus or environmental changes
occur. It follows the general adaptive landscape concept initially
proposed by (Wright, 1931). The possible acquisition of increased
resistance to the deleterious effects of mutations by virtue of viruses
ﬁnding a ﬂat ﬁtness surface was predicted by theoretical studies
(Schuster and Swetina, 1988; Wilke et al., 2001), and it has been
supported by some experimental results. A VSV mutant behaved as aneutral mutant relative to the wild type virus under standard
replication conditions, but displayed a selective disadvantage when
environmental perturbations intervened during competitive replica-
tion (Quer et al., 1996). In particular, FU mutagenesis prompted the
dominance of the wild type over the mutant VSV. The neutral mutant
included a number of mutations relative to the wild type that might
have rendered it vulnerable to additional mutations (Quer et al., 2001).
Evidence of robustness has been also obtained with viroids replicating
in UV-irradiated plants (Codoner et al., 2006).
In view of this previous evidence, and due to the relevance of a
possiblemutational robustness to the detrimental effects of mutations
in a lethal mutagenesis approach, we have examined whether
enhanced mutagenesis resulted in selection of variants of the
prototypic LCMV that displayed mutational robustness, and thereby
jeopardize the use of lethal mutagenesis as an antiviral strategy to
combat arenavirus infections. Notably, several arenaviruses, chieﬂy
Lassa virus, are a group of highly signiﬁcant human pathogens for
which no effective vaccines, and only limited possibilities for
pharmacological intervention, are currently available [reviewed in
Oldstone, 2002]. Furthermore, evidence indicates that LCMV is a
neglected humanpathogen (Fischer et al., 2006; Jamieson et al., 2006).
The LCMV genome consists of two segments of single stranded RNA
(small or S, of 3376 nucleotides; large or L, of 7228 nucleotides) of
negative polarity. Each segment uses an ambisense coding strategy to
direct the synthesis of two viral polypeptides. The S segment encodes
the virus nucleoprotein (NP) and glycoprotein precursor GPC, which is
posttranslationally processed into mature GP1 and GP2 proteins via
proteolytic cleavage by the cellular protease S1P. The L segment
encodes the virus RNA-dependent RNA polymerase (L polymerase)
and the small RING ﬁnger protein Z that is the counterpart of the
matrix (M) protein found in many other enveloped negative strand
RNA viruses (Buchmeier et al., 2007). LCMV is highly sensitive to FU-
mediated extinction (Grande-Pérez et al., 2002; Ruiz-Jarabo et al.,
2003), and contributed the ﬁrst proof of principle of the feasibility of a
lethal mutagenesis approach in vivo, by documenting that FU
prevented the establishment of a persistent LCMV infection in mice
(Ruiz-Jarabo et al., 2003). Here we provide evidence against evolution
of LCMV towards mutational robustness in the course of mutagenesis
treatments that eventually lead to virus extinction.
Results
Sensitivity to 5-ﬂuorouracil mutagenesis of LCMV populations with or
without a history of 5-ﬂuorouracil mutagenesis
LCMV (Arm 53b) can be extinguished by treatment with FU in a
dose-dependent manner (Grande-Pérez et al., 2002; Ruiz-Jarabo et al.,
2003). In serial, low multiplicity of infection (m.o.i.) passages in BHK-
21 cells (as detailed inMaterials andmethods), concentrations of FU of
50 to 100 μg/ml resulted in virus extinction in 2 to 3 passages, while FU
concentrations of 10 to 20 μg/ml resulted in reduction of virus titer but
no viral extinction for at least 13 passages (Grande-Pérez et al., 2002;
Martín et al., unpublished results).We chose four LCMV populations to
test their sensitivity to FUmutagenesis: Cp5 and Cp9, that correspond
to LCMV serially passaged in BHK-21 cells 5 and 9 times, respectively,
in the absence of FU; and FU-20p5 and FU-20p9 that correspond to
LCMV serially passaged in BHK-21 cells 5 and 9 times, respectively, in
the presence of 20 μg/ml FU (Fig. 1). Duplicate samples of the four
populations were subjected to three additional serial passages either
in the absence or the presence of FU (100 μg/ml). In all cases, ex-
tinction occurred in the ﬁrst or second passage in the presence of FU,
and not in its absence (Fig. 2). Extinction was ascertained by absence
of infectivity and absence of speciﬁc RT-PCR ampliﬁable, LCMV-
speciﬁc sequences, after three blind passages of the viral population in
the absence of mutagens, as detailed in Materials and methods. Thus,
the results conﬁrm the sensitivity to FU-induced lethal mutagenesis of
Fig. 2. Evolution of four different LCMV quasispecies during serial passages in the absence or presence of FU. The LCMV populations used are described in the panel on the right. A and
B correspond to duplicate experiments carried out in parallel, using the same initial viral preparations. In each passage virus was harvested, titrated, and used for the next infection at
a m.o.i. of 0.01 pfu/cell (3×106 cells infected with 3×104 pfu of virus). All populations were titrated at each passage. Absence of a bar means titer below the limit of detection (33 pfu/
ml). Procedures are detailed in Materials and methods.
Fig.1. Passage history of LCMV quasispecies to yield the clones and populations used in the present study. Serial passages of LCMV Arm 53b in BHK-21 cells in the absence (−FU) or the
presence (+FU) of FU, and the several sublineages involved in the present study are indicated by thick arrows, that link uncloned populations (depicted as open circles); p followed by
a number indicates the passage number. Each passage involved the infection of 3–9×106 BHK-21 cells with 3×104 to 9×104 pfu of LCMV. Thin arrows indicate the isolation of
biological clones (virus from individual plaques) after dilution of virus and plating on Vero cell monolayers in the absence of FU; biological clones are depicted as ﬁlled squares.
Procedures are detailed in Materials and methods.
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Fig. 3. Infectivity of three biological clones from each of four different LCMV quasispecies during serial passages in the absence or presence of FU. Virus titers for the initial clones and for passages 1 and 3 (p1, p3, respectively) are given for the
four LCMV quasispecies analyzed in the present study (compare with Fig. 1); the presence or absence of FU (100 µg/ml) is indicated in the right inset of each panel. Each value is the mean of at least three separate experiments; standard
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FU, and provide no evidence of acquisition of mutational robustness of
LCMV in the course of mutagenesis.
Sensitivity to 5-ﬂuorouracil mutagenesis of biological clones of LCMV
isolated from populations with or without a history of 5-ﬂuorouracil
mutagenesis
Mutagenized LCMV populations contain defective genomes that
can interfere with the replication of infectious LCMV, and may
contribute to virus extinction, in agreement with the lethal defection
model of virus extinction (Grande-Pérez et al., 2005b) (see Introduc-
tion). Therefore, it could be argued that the sensitivity of uncloned
LCMV populations to FU was favored by defector genomes present in
the population, but that biological clones from the populations treated
with FU had acquired mutational robustness. To test this possibility, 3
biological clones from each of the LCMV populations Cp5, Cp9, FU-
20p5 and FU-20p9 were isolated (as described in Materials and
methods), and subjected to 3 serial passages either in the absence or
presence of FU (100 μg/ml). Extinction was observed at passage 2 to 3
for all clones passaged in the presence of FU, and not in its absence
(Fig. 3), irrespective of the prior history of FU-induced mutagenesis of
the populations fromwhich the clones were isolated. No difference in
the time (number of passages) required to reach extinction was
observed between clones isolated from populations without a history
of FU treatment (Cp5, Cp9) and those with a history of FU treatment
(FU-20p5, FU-20p9) (Fig. 3). Thus both, uncloned LCMV populations,
and biological clones derived from those populations, did not show
any resistance to FU-induced extinction, despite a prior history of FU
mutagenesis.
Discussion
Lethal mutagenesis is currently under intense investigation as a
potential new antiviral strategy, with an ongoing phase 2 clinical trial
with AIDS patients under treatment with an antiviral mutagenic
nucleoside analogue (Harris et al., 2005). New nucleotide analogues
are currently under study that could ﬁnd an application in lethal
mutagenesis of viruses (Harki et al., 2006; Graci et al., 2007; Harki
et al., 2007; Graci et al., 2008; Moriyama et al., 2008). A possible
clinical application of lethal mutagenesis to persistent ribovirus and
retrovirus infections is encouraged by the documented extinction of
many viruses as a result of their replication in the presence of
mutagenic agents [reviewed in Graci and Cameron, 2002; Anderson
et al., 2004; Domingo, 2005]. Decreases in viral load as a result of
enhanced mutagenesis of the virus may contribute to virus clearance
by the host immune response. Therefore, it is of utmost importance to
identify those mechanisms that may lead to selection of viral mutants
(or viral populations) resistant to the mutagenic treatment, and that
may permit viruses to evade extinction. The question is particularly
pertinent given the widespread occurrence of viruses resistant to (or
even dependent on) antiviral inhibitors (Domingo, 2003; Figlerowicz
et al., 2003; Baldwin and Berkhout, 2007). At least two extinction-
escape mechanisms can be envisaged: (i) selection of virus mutants
that, because of substitutions in the viral polymerase, are deﬁcient in
the incorporation of one or several mutagenic nucleotide analogues,
and (ii) acquisition of mutational robustness (insensitivity to the
deleterious effects ofmutations). Mechanism (i) has been documented
with the isolation of PV, HCV and FMDV polymerase mutants with
decreased sensitivity to ribavirin (Pfeiffer and Kirkegaard, 2003,
2005b; Vo et al., 2003; Pfeiffer and Kirkegaard, 2005b; Vignuzzi
et al., 2006; Sierra et al., 2007). Mechanism (ii) has been proposed
on the basis of the comparison of two VSV populations, but the
molecular basis underlying the increased mutational robustness
attributed to one of the VSV populations was not identiﬁed (Sanjuan
et al., 2007).Mutational robustness has been suggested as a mechanism for
viruses to reach a mutation-selection balance in the face of high
mutation rates during RNA genome replication and retrotranscription
(Drake and Holland, 1999; Holland, 2006; Domingo, 2007). Robust-
ness offers a mechanism by which viruses can avoid (or attenuate) the
deleterious effects of mutations. The proposal assumes that viruses
can evolve to increase the fraction of genomic residues that are neutral
or quasi-neutral [reviewed in Wilke and Adami, 2003], but the
molecular events underlying such evolution are not known. Since it
has been proposed that high mutation rates favor evolution towards
mutational robustness (Montville et al., 2005; Elena et al., 2007), time
was ripe to suggest that mutational robustness could be a mechanism
to escape lethal mutagenesis (Sanjuan et al., 2007).
In the present study, we have found no evidence of even minimal
alterations of sensitivity to extinction, either of uncloned LCMV
populations or of biological clones, after treatment with FU. Not even a
trend towards anyminimal increased resistance to extinctionwas noted
in LCMV populations or clones that had been subjected to 9 passages in
the presence of FU, when compared either with their parental
populations or with passaged populations not subjected to FU
mutagenesis. It could be argued that many more replication rounds
might be needed for LCMV to evolve towards mutational robustness.
However, nine passages are more than double the number of passages
needed for LCMVextinction under conditions of lethalmutagenesis, and
here we have tested robustness as a possible impairment of virus
extinction. The number of passages allowed for LCMV to acquire
robustness was commensurate with the number of passages required
for extinction (Grande-Pérez et al., 2002, 2005a,b; Ruiz-Jarabo et al.,
2003; Grande-Pérez et al., 2005a,b). Therefore, mutational robustness
suggested as a resistance mechanism against lethal mutagenesis
(Sanjuan et al., 2007) does not operate in LCMV under our experimental
conditions, and, therefore, robustness cannot be regarded as a general
mechanism of resistance to lethal mutagenesis. Contrary to detection of
ribavirin-resistant mutants of FMDV (Sierra et al., 2007), we have failed
to obtain FMDV or LCMV populations that show decreased sensitivity to
FU. Althoughwe cannot exclude that suchmutants might be eventually
obtained, and that viral polymerases with decreased capacity to
incorporate FU might exist, our current evidence suggests that they
areunlikely tobe readily selectedduringa lethalmutagenesis treatment.
Basic observations with RNA virus genomes and their evolution
render unlikely mutational robustness as a mechanism to escape lethal
mutagenesis. One is that in RNA viruses both the genome itself and
encoded proteins (most of them multifunctional) determine the viral
phenotype. Therefore, the neutral space of genomic nucleotides must
be extremely reduced in RNA viruses. Despite theoretical and experi-
mental evidence of RNA genome populations displaying different
sensitivity to mutations (Quer et al., 1996, 2001; Wilke et al., 2001;
Codoner et al., 2006; Schuster and Stadler, 2008) it is unlikely that a
pathway towards increased robustness can be found under the
enhanced mutagenesis conditions and within the time span inherent
to a lethal mutagenesis treatment. A revealing comparison has been
provided by biological FMDV clones that accumulated mutations (that
reached 1.5×10−2 substitutions per genomic nucleotide), following 409
plaque-to-plaque transfers, without extinction (Escarmís et al., 2008).
Experimental and in silico evidence suggests that the occurrence at low
frequency of compensatory mutations allowed viral subpopulations to
be refounded for virus survival regardless of extinction of many clones
present in the population (Lázaro et al., 2002, 2003; Manrubia et al.,
2005; Escarmís et al., 2008). Despite FMDV harbouring a potential for
survival of minority subpopulations, no such a survival has been
observed when the same FMDV clones were subjected to lethal
mutagenesis (Pariente et al., 2005; Escarmís et al., 2008). No
compensatory mutations could be selected in the face of heavy
mutagenesis, and no slow-replicating subpopulations, if they were
present, could ﬁnd their way towards dominance in the populations.
Modulation of replication rate is likely to require multiple coordinated
190 V. Martín et al. / Virology 378 (2008) 185–192mutations at both the polymerase and other accompanying proteins.
Such requirements are unlikely to be achieved under enhanced
mutagenesis, unless slowly-replicating, mutagenesis-refractory sub-
populations preexisted in substantial proportions in the evolving RNA
viral quasispecies. Experimental evidence to support this possibility is
lacking.
Evidence suggests that real viruses do not move within smooth
ﬁtness landscapes (Wright, 1931, 1982) but, rather, that they move
through rough landscapes. It is extremely unlikely than in a short time
(limited number of replication rounds) a virus will encounter the ﬂat
ﬁtness surface to render it robust to mutations, andmore so under the
instability conditions enforced by enhanced mutagenesis. Evidence
points towards long-termevolution as themore realistic conditions for
viruses to increase mutational robustness. The case of the VSV mutant
that lost its neutrality under FUmutagenesis (and other environmental
perturbations) (Quer et al., 1996, 2001) involved a relatively enhanced
resistance to mutagenesis of the wild type VSV relative to the mutant,
but certainlywild typeVSVwasnot located in aﬁtness surface of such a
nature as to render it insensitive to enhanced mutagenesis. This was
extensively documented in the pioneer studies of John Holland and
colleagues on error catastrophe of wild type VSV (Holland et al., 1990;
Lee et al., 1997). We conclude that mutational robustness of LCMV is
unlikely to play any signiﬁcant role in preventing or delaying lethal
mutagenesis of LCMV during replication in BHK-21 cells.
Materials and methods
Cells and virus
Virus infections and maintenance of baby hamster kidney (BHK-
21) and Vero cells were carried out as described (Sierra et al., 2000;
Grande-Pérez et al., 2002; Meyer et al., 2002). LCMV strain Armstrong
(Arm) 53b is a triple plaque-puriﬁed clone from LCMV Arm CA
passaged four times in BHK-21 cells. Virus infectivity in samples from
the supernatant of infected cultures was determined by plaque assay
on Vero cell monolayers, because the virus does not form lytic plaques
on BHK-21 cells. Vero cell monolayers (1×106 cells in six-well dishes)
were infected in duplicate with serial dilutions of the virus prepara-
tions. After 90 min of absorption at 37 °C, 7% CO2, the virus was
removed and cells were overlaid with 4 ml of DMEM supplemented
with 0.7% FCS, 2% L-glutamine/50 μg/ml, gentamicin, and 0.3% agar.
After 7 days, cells were stained with 2% crystal violet in 2%
formaldehyde, and viral plaques were counted.
History of the viral quasispecies used
Four different LCMV quasispecies were chosen from previous work
(Grande-Pérez et al., 2002). Cp5 and Cp9 are LCMV Arm 53b passaged
in BHK-21 cells ﬁve and nine times, respectively, in absence of FU. Each
passage involved infection of 3–9×106 cells with 3–9×104 104 pfu of
LCMV. FU-20p5 and FU-20p9 are LCMV Arm 53b passaged in BHK-21
cells ﬁve and nine times, respectively, in presence of 20 μg/ml of FU.
This concentration of FU was not sufﬁcient to lead to LCMV extinction
(Grande-Pérez et al., 2002). Each passage involved infection of 3–
9×106 cells with 3–9×104 104 pfu of LCMV (Grande-Pérez et al., 2002).
Virus infections
Semiconﬂuent monolayers of BHK-21 (3×106 cells in 100-mm
diameter dishes) were infected at a m.o.i. of 0.01 pfu per cell, in 10 ml
of DMEM supplemented with 10% FCS, 2% L-glutamine, 0.52% glucose
and 50 μg/ml gentamicin, either in the absence or the presence of FU
(200 μg/ml), following described procedures (Grande-Pérez et al.,
2002). Supernatants from infected cells (and from mock-infected
cells) were harvested 48 h postinfection, clariﬁed by centrifugation at
2500 rpm for 30min at 4 °C, and stored at −80 °C. Virus infectivity wasdetermined by plaque assay on Vero cell monolayers as described
(Ahmedet al.,1988). Infectivity ranged from3.6×105 to 3.4×108 pfu/ml
in the absence of FU, and 1.3×106 to b33 pfu/ml in the presence of FU.
The absence of plaques in supernatants from mock-infected cultures
ascertained the absence of contaminationwith virus. Values shown are
the mean of at least three determinations.
Selection of individual biological clones from LCMV quasispecies
Vero cells monolayers (1×106 cells in six-well dishes) were
infected with serial dilutions of LCMV, and after 90 minutes of
adsorption, the virus was removed and cells were overlaid with 4 ml
of DMEM (without phenol red), and supplemented with 0.7% FCS, 2%
L-glutamine/50 μg/ml, gentamicin, 0.3% agar. No FU was included in
the medium. After 4–5 days, virus from individual plaques were
visualized under visible light (facilitated by absence of phenol red),
and the contents of individual plaques were resuspended in 500 μl of
DMEM without FCS, and titrated. Titer of resuspended LCMV bio-
logical clones and passaged once in M-24 well ranged from 104 to
107 pfu/ml.
Drug treatment
Preparation of FU stock solutions, determination of BHK-21 cell
viability, and procedures for infections in the presence of this
mutagenic base analogue were performed as described (Grande-
Pérez et al., 2002). Al least 80% cell survival was scored after the FU
treatments performed in the present study, in agreement with
previous determination (Sierra et al., 2000). LCMV was considered
extinguished when no reverse transcriptase-PCR (RT-PCR)-ampliﬁ-
able material, and no infectivity (b33 pfu/ml, limit of detection) could
be observed after three blind passages of the undiluted viral
population in BHK-21 cells in standard culture medium, in the
absence of mutagens (Sierra et al., 2000; Pariente et al., 2001).
RNA extraction and reverse transcription PCR
RNA was extracted with Trizol (Invitrogen) from supernatants of
infected cultures, following the manufacturer's protocol. RNAs were
ampliﬁed by RT-PCR by using ThermoScript reverse transcriptase
(Invitrogen) and a reverse (antisense) primer at 60 °C for 45 min,
followed by PCR with Pfu DNA polymerase (Promega). cDNAs were
analyzed by agarose gel electrophoresis.
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